Management and outcome of French elderly patients with lung cancer: An IFCT survey

被引:23
作者
Quoix, E. [1 ]
Monnet, I. [2 ]
Scheid, P. [3 ]
Hamadouche, A. [4 ]
Chouaid, C. [5 ]
Massard, G. [6 ]
Depierre, A. [7 ]
Souquet, P. -J. [8 ]
Braun, D. [9 ]
Girard, P. [10 ]
Breton, J. -L. [11 ]
Lebitasy, M. -P. [12 ]
Milleron, B. [13 ]
机构
[1] Univ Strasbourg, Hop Univ, Nouvel Hop Civil, Serv Pneumol, F-67091 Strasbourg, France
[2] CHIC, Serv Pneumol, F-94000 Creteil, France
[3] Hop Brabois, Serv Pneumol, F-54500 Vandoeuvre Les Nancy, France
[4] Univ Strasbourg, Fac Med, Dept Epidemiol, F-67000 Strasbourg, France
[5] Hop St Antoine, Serv Pneumol, F-75012 Paris, France
[6] Univ Strasbourg, Hop Univ, Serv Chirurg Thorac, F-67091 Strasbourg, France
[7] Hop Jean Minjoz, Serv Pneumol, F-25000 Besancon, France
[8] CHU Lyon Sud, Serv Pneumol, F-69310 Pierre Benite, France
[9] CHG Briey, Serv Pneumol, F-54151 Briey, France
[10] Inst Mutualiste Montsouris, Serv Pneumol, F-75014 Paris, France
[11] CHG Belfort, Serv Pneumol, F-90000 Belfort, France
[12] IFCT, F-75009 Paris, France
[13] Hop Tenon, Serv Pneumol, F-75020 Paris, France
关键词
Elderly; Lung cancer; Management; Early death; Smoking habits; SURVIVAL; CHEMOTHERAPY; STAGE; OLDER; AGE; UNDERREPRESENTATION; MORTALITY; PATTERNS; ONCOLOGY; TRENDS;
D O I
10.1016/j.rmr.2010.02.013
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Background. - Lung cancer in the elderly is considerably increasing in frequency, representing a public health issue. Those patients are underrepresented in clinical trials and probably not optimally treated. Methods. - We performed a survey of the management and the outcome of lung cancer patients aged 70 and more in France between August 2002 and September 2003 according to age categories (70-74, 75-79 and >= 80 years). One thousand six hundred and twenty-seven patients were analysed for descriptive data and 1595 for survival. Results. - Median age was 75 (70-96) and male:female ratio was 4.26 with a decrease across the age categories from 5.1 to 3.0. Tobacco-linked comorbidities were frequent. The median value of Charlson's index was 2. About 58% had a performance status (PS) 0 or 1, 30% a PS 2 and 12% a PS > 2. The proportion of never-smokers (11.6%) increased significantly with age categories. Regarding imaging procedures, as much as 83.3% of the patients had at least a chest CT-scan and a brain CT-scan (or MRI) and an abdominal ultrasound or CT-scan. Best Supportive Care (BSC) as only treatment was administered to 16.1% of the patients. Among patients specifically treated, 22.9% were operated, 21.8% received mediastinal irradiation and 71.5% chemotherapy. Overall, median survival time was 9.14 months with 23.5% deaths occurring before 3 months. Low category of age, good PS, non-smoking and high body mass index (BMI) were favorable independent prognostic factors of survival. Age, PS and tobacco smoking were prognostic of early death. Conclusions. - A large majority of elderly lung cancer patients in France are managed like younger counterparts regarding diagnostic procedures and treatment. Age remains an independent prognostic factor as well for overall survival as for early death. (C) 2010 SPLF. Published by Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:421 / 430
页数:10
相关论文
共 38 条
[1]   SURVIVAL DETERMINANTS IN EXTENSIVE-STAGE NON-SMALL-CELL LUNG-CANCER - THE SOUTHWEST-ONCOLOGY-GROUP EXPERIENCE [J].
ALBAIN, KS ;
CROWLEY, JJ ;
LEBLANC, M ;
LIVINGSTON, RB .
JOURNAL OF CLINICAL ONCOLOGY, 1991, 9 (09) :1618-1626
[2]   Women and lung cancer - Waiting to exhale [J].
Baldini, EH ;
Strauss, GM .
CHEST, 1997, 112 (04) :S229-S234
[3]   Geriatric oncology: challenges for the new century [J].
Balducci, L .
EUROPEAN JOURNAL OF CANCER, 2000, 36 (14) :1741-1754
[4]   Cancer incidence and mortality in France over the period 1980-2005 [J].
Belot, A. ;
Grosclaude, P. ;
Bossard, N. ;
Jougla, E. ;
Benhamou, E. ;
Delafosse, P. ;
Guizard, A. -V. ;
Molinie, F. ;
Danzon, A. ;
Bara, S. ;
Bouvier, A. -M. ;
Tretarre, B. ;
Binder-Foucard, F. ;
Colonna, M. ;
Daubisse, L. ;
Hedelin, G. ;
Launoy, G. ;
Le Stang, N. ;
Maynadie, M. ;
Monnereau, A. ;
Troussard, X. ;
Faivre, J. ;
Collignon, A. ;
Janoray, I. ;
Arveux, P. ;
Buemi, A. ;
Raverdy, N. ;
Schvartz, C. ;
Bovet, M. ;
Cherie-Challine, L. ;
Esteve, J. ;
Remontet, L. ;
Velten, M. .
REVUE D EPIDEMIOLOGIE ET DE SANTE PUBLIQUE, 2008, 56 (03) :159-175
[5]  
Blanchon F, 2002, REV MAL RESPIR, V19, P727
[6]   A NEW METHOD OF CLASSIFYING PROGNOSTIC CO-MORBIDITY IN LONGITUDINAL-STUDIES - DEVELOPMENT AND VALIDATION [J].
CHARLSON, ME ;
POMPEI, P ;
ALES, KL ;
MACKENZIE, CR .
JOURNAL OF CHRONIC DISEASES, 1987, 40 (05) :373-383
[7]   Who gets chemotherapy for metastatic lung cancer? [J].
Earle, CC ;
Venditti, LN ;
Neumann, PJ ;
Gelber, RD ;
Weinstein, MC ;
Potosky, AL ;
Weeks, JC .
CHEST, 2000, 117 (05) :1239-1246
[8]   Measuring comorbidity in older cancer patients [J].
Extermann, M .
EUROPEAN JOURNAL OF CANCER, 2000, 36 (04) :453-471
[9]   Non-small-cell lung cancer in a French department, (1982-1997):: management and outcome [J].
Foeglé, J ;
Hédelin, G ;
Lebitasy, MP ;
Purohit, A ;
Velten, M ;
Quoix, E .
BRITISH JOURNAL OF CANCER, 2005, 92 (03) :459-466
[10]   Specific features of non-small cell lung cancer in women: A retrospective study of 1738 cases diagnosed in Bas-Rhin between 1982 and 1997 [J].
Foegle, Jacinthe ;
Hedelin, Guy ;
Lebitasy, Marie-Paule ;
Purohit, Ashok ;
Velten, Michel ;
Quoix, Elisabeth .
JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (06) :466-474